• Systematic review examines Fusobacterium nucleatum as predictor of treatment response

    A systematic review evaluated whether Fusobacterium nucleatum, a bacterium implicated in CRC progression and immune modulation, can predict treatment response, though its role as a biomarker remains unclear. (Cancer Treatment Reviews)